Fundz

Fundz Deep Dive

Everything you need to win TransThera Sciences (Nanjing) — in one platform.

Who to reach, what to say, and why now on TransThera Sciences (Nanjing) — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on TransThera Sciences (Nanjing) — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

TransThera Sciences Partners with Neurocrine to Develop NLRP3 Inhibitors for Treating Multiple Diseases.

Nov 03, 2025•8 months ago

Contract Type

partnership

Nanjing CityBiotechnologyHealth CarePharmaceutical

Description

TransThera Sciences has entered into a partnership with Neurocrine Biosciences to develop NLRP3 inhibitors. The agreement allows Neurocrine exclusive rights outside Greater China while TransThera retains rights within the region, including potential milestone payments up to $881.5 million.

Company Information

Company

TransThera Sciences (Nanjing)

Location

Nanjing City, Jiangsu, China

About

TransThera Sciences (Nanjing), Inc. is a joint stock company based in China, focusing on the development of pharmaceutical products. The company is engaged in the research and development of innovative therapies, particularly in the area of NLRP3 inhibitors for treating multiple diseases.

Predictive Intelligence
Strategic

ML-powered predictions for TransThera Sciences (Nanjing)'s next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.